Article
Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
Blood - 2 May 2024
Liu Jiuyang, Li Shuran, Wang Qin, Feng Yingcai, Xing Haimei, Yang Xuefei, Guo Ying, Guo Yunhang, Sun Hanzi, Liu Xiaoxin, Yang Shasha, Mei Zhu, Zhu Yutong, Cheng Zhenzhen, Chen Shuaishuai, Xu Min, Zhang Wenjing, Wan Nanyan, Wang Jia, Ma Yanwen, Zhang Shuo, Luan Xudong, Xu Aiying, Li Lin, Wang Haitao, Yang Xiaolong, Hong Yuan, Xue Hai, Yuan Xi, Hu Nan, Song Xiaomin, Wang Zhiwei, Liu Xuesong, Wang Lai, Liu Ye
Abstract excerpt
ABSTRACT: Venetoclax, the first-generation inhibitor of the apoptosis regulator B-cell lymphoma 2 (BCL2), disrupts the interaction between BCL2 and proapoptotic proteins, promoting the apoptosis in malignant cells. Venetoclax is the mainstay of therapy for relapsed chronic lymphocytic leukemia and is under investigation in multiple clinical trials for the treatment of various cancers. Although venetoclax...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.